The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway-Reference-Cited by-同舟云学术

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

Published:2012-12 Issue:52 Volume:287 Page:43492-43501
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Luna Saavedra Yascara Grisel,Day Robert,Seidah Nabil G.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference42 articles.

1. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1). Liver regeneration and neuronal differentiation;Seidah;Proc. Natl. Acad. Sci. U.S.A.,2003

2. The biology and therapeutic targeting of the proprotein convertases;Seidah;Nat. Rev. Drug Discov.,2012

3. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat. Genet.,2003

4. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation;Marduel;Hum. Mutat.,2012

5. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol;Benjannet;J. Biol. Chem.,2004

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C;Cells;2024-05-17

2. PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis;Journal of Cellular Biochemistry;2024-05-15

3. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022;Frontiers in Endocrinology;2023-11-29

4. Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations;Scientific Reports;2023-11-13

5. Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis;The Journal of Clinical Pharmacology;2023-10-02